基于精准医学的糖尿病临床分型研究进展
Research Progress on Clinical Classification of Diabetes Based on Precision Medicine
DOI: 10.12677/ACM.2024.141019, PDF,   
作者: 张 玉, 王 宁, 赵婷婷：新疆医科大学第一附属医院综合内一科，新疆 乌鲁木齐
关键词: 糖尿病；精准医学；分型；Diabetes Mellitus； Precision Medicine； Classification
摘要: 糖尿病是一种以高血糖为特征的疾病群，仅依据血糖作为糖尿病的诊疗标准，不能完全揭示这种高度异质性疾病的本质，且目前传统的糖尿病分型方法不能实现个体化治疗及早期预防并发症的需求。随着科技的进步以及对糖尿病病因、病理机制的深入研究，糖尿病在传统分型基础上出现越来越细致的分型方法，精准医学的出现也为糖尿病的研究及临床防控提供了新思路。本综述总结现阶段有关糖尿病临床分型的研究进展，为糖尿病精准医学提供方向。
Abstract: Diabetes mellitus is a group of diseases characterized by hyperglycemia, the diagnosis and treat-ment standard of diabetes mellitus based on blood glucose alone cannot fully reveal the nature of this highly heterogeneous disease, the current traditional typing methods of diabetes mellitus can-not realize the needs of individualized treatment and early prevention of complications. With the advancement of science and technology and in-depth research on the etiology and pathogenesis of diabetes, more and more detailed typing methods have emerged on the basis of traditional typing of diabetes, and the emergence of precision medicine has also provided new ideas for diabetes re-search and clinical prevention and control. This review summarizes the current stage of research progress on clinical typing of diabetes mellitus and provides a direction for precision medicine of diabetes mellitus.
文章引用：张玉, 王宁, 赵婷婷. 基于精准医学的糖尿病临床分型研究进展[J]. 临床医学进展, 2024, 14(1): 131-136. https://doi.org/10.12677/ACM.2024.141019

参考文献

[1] Saeedi, P., Petersohn, I., Salpea, P., et al. (2019) Global and Regional Diabetes Prevalence Estimates for 2019 and Pro-jections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th Edition. Diabetes Re-search and Clinical Practice, 157, Article ID: 107843. [Google Scholar] [CrossRef] [PubMed]
[2] Sun, H., Saeedi, P., Karuranga, S., et al. (2022) IDF Diabetes Atlas: Global, Regional and Country-Level Diabetes Prevalence Es-timates for 2021 and Projections for 2045. Diabetes Research and Clinical Practice, 183, Article ID: 109119. [Google Scholar] [CrossRef] [PubMed]
[3] NCD Risk Factor Collaboration (NCD-RisC) (2017) World-wide Trends in Body-Mass Index, Underweight, Overweight, and Obesity from 1975 to 2016: A Pooled Analysis of 2416 Population-Based Measurement Studies in 1289 Million Children, Adolescents, and Adults. The Lancet, 390, 2627-2642.
[4] Alberti, K.G. and Zimmet, P.Z. (1998) Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus Provisional Report of a WHO Consulta-tion. Diabetic Medicine, 15, 539-553. [Google Scholar] [CrossRef] 
[5] Inzucchi, S.E., Ber-genstal, R.M., Buse, J.B., et al. (2012) Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 35, 1364-1379. [Google Scholar] [CrossRef] [PubMed]
[6] Chung, W.K., Erion, K., Florez, J.C., et al. (2020) Precision Medicine in Diabetes: A Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 43, 1617-1635. [Google Scholar] [CrossRef] [PubMed]
[7] Nolan, J.J., Kahkoska, A.R., Semnani-Azad, Z., et al. (2022) ADA/EASD Precision Medicine in Diabetes Initiative: An International Perspective and Future Vision for Precision Medicine in Dia-betes. Diabetes Care, 45, 261-266. [Google Scholar] [CrossRef] [PubMed]
[8] Tobias, D.K., Merino, J., Ahmad, A., et al. (2023) Second International Consensus Report on Gaps and Opportunities for the Clinical Translation of Precision Diabetes Medicine. Nature Medi-cine, 29, 2438-2457. [Google Scholar] [CrossRef] [PubMed]
[9] Nkonge, K.M., Nkonge, D.K. and Nkonge, T.N. (2020) The Epidemiology, Molecular Pathogenesis, Diagnosis, and Treatment of Maturity-Onset Diabetes of the Young (MODY). Clinical Diabetes and Endocrinology, 6, Article No. 20. [Google Scholar] [CrossRef] [PubMed]
[10] Laver, T.W., Wakeling, M.N., et al. (2022) Evaluation of Evidence for Pathogenicity Demonstrates That BLK, KLF11, and PAX4 Should Not Be Included in Diagnostic Testing for MODY. Diabetes, 71, 1128-1136. [Google Scholar] [CrossRef] [PubMed]
[11] Forlani, G., Zucchini, S., Di Rocco, A., et al. (2010) Double Heterozygous Mutations Involving Both HNF1A/MODY3 and HNF4A/MODY1 Genes: A Case Report. Diabetes Care, 33, 2336-2338. [Google Scholar] [CrossRef] [PubMed]
[12] Kant, R., Davis, A. and Verma, V. (2022) Maturity-Onset Di-abetes of the Young: Rapid Evidence Review. American Family Physician, 105, 162-167.
[13] Broome, D.T., Pantalone, K.M., Kashyap, S.R. and Philipson, L.H. (2021) Approach to the Patient with MODY- Monogenic Diabetes. The Jour-nal of Clinical Endocrinology and Metabolism, 106, 237-250. [Google Scholar] [CrossRef] [PubMed]
[14] Li, J., Shu, M., Wang, X., et al. (2021) Precision Therapy for a Chi-nese Family with Maturity-Onset Diabetes of the Young. Frontiers in Endocrinology, 12, Article 700342. [Google Scholar] [CrossRef] [PubMed]
[15] Kahraman, S., Dirice, E., Basile, G., et al. (2022) Abnormal Exo-crine-Endocrine Cell Cross-Talk Promotes β-Cell Dysfunction and Loss in MODY8. Nature Metabolism, 4, 76-89. [Google Scholar] [CrossRef] [PubMed]
[16] (1965) Diabetes Mellitus. Report of a WHO Expert Committee. World Health Organization Technical Report Series, 310, 1-44.
[17] (1980) WHO Expert Committee on Diabetes Mellitus: Second Report. World Health Organization Technical Report Series, 646, 1-80.
[18] The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus; Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 20, 1183-1197. [Google Scholar] [CrossRef] [PubMed]
[19] World Health Organization (2019) Classifica-tion of Diabetes Mellitus, 2019. WHO Document Production Services, Geneva.
[20] Brooks-Worrell, B.M., Reichow, J.L., Goel, A., Ismail, H. and Palmer, J.P. (2011) Identification of Autoantibody- Negative Autoimmune Type 2 Diabetic Patients. Diabetes Care, 34, 168-173. [Google Scholar] [CrossRef] [PubMed]
[21] Liang, H., Cheng, Y., Tang, W., et al. (2019) Clinical Manifestation and Islet β-Cell Function of a Subtype of Latent Autoimmune Diabetes in Adults (LADA): Positive for T Cell Responses in Phenotypic Type 2 Diabetes. Acta Diabetologica, 56, 1225-1230. [Google Scholar] [CrossRef] [PubMed]
[22] McKeigue, P.M., Spiliopoulou, A., McGurnaghan, S., et al. (2019) Persistent C-Peptide Secretion in Type 1 Diabetes and Its Relationship to the Genetic Architecture of Diabetes. BMC Medicine, 17, Article No. 165. [Google Scholar] [CrossRef] [PubMed]
[23] Buzzetti, R., Di Pietro, S., Giaccari, A., et al. (2007) High Titer of Autoantibodies to GAD Identifies a Specific Phenotype of Adult-Onset Autoimmune Diabetes. Diabetes Care, 30, 932-938. [Google Scholar] [CrossRef] [PubMed]
[24] Zhou, Z., Xiang, Y., Ji, L., et al. (2013) Frequency, Immunoge-netics, and Clinical Characteristics of Latent Autoimmune Diabetes in China (LADA China Study): A Nationwide, Mul-ticenter, Clinic-Based Cross-Sectional Study. Diabetes, 62, 543-550. [Google Scholar] [CrossRef] [PubMed]
[25] Ahlqvist, E., Storm, P., Käräjämäki, A., et al. (2018) Novel Subgroups of Adult-Onset Diabetes and Their Association with Outcomes: A Data-Driven Cluster Analysis of Six Variables. The Lancet Diabetes & Endocrinology, 6, 361-369. [Google Scholar] [CrossRef] 
[26] Bennet, L., Nilsson, C., Mansour-Aly, D., et al. (2021) Adult-Onset Diabetes in Middle Eastern Immigrants to Sweden: Novel Subgroups and Diabetic Complications—The All New Diabetes in Scania Cohort Diabetic Complications and Ethnicity. Diabetes/Metabolism Research and Reviews, 37, e3419. [Google Scholar] [CrossRef] [PubMed]
[27] Fedotkina, O., Sulaieva, O., Ozgumus, T., et al. (2021) Novel Re-classification of Adult Diabetes Is Useful to Distinguish Stages of β-Cell Function Linked to the Risk of Vascular Com-plications: The DOLCE Study from Northern Ukraine. Frontiers in Genetics, 12, Article 637945. [Google Scholar] [CrossRef] [PubMed]
[28] Zou, X., Zhu, Z. and Ji, L. (2019) Novel Subgroups of Patients with Adult-Onset Diabetes in Chinese and US Populations. The Lancet Diabetes & Endocrinology, 7, 9-11. [Google Scholar] [CrossRef] 
[29] Slieker, R.C., Donnelly, L.A., Fitipaldi, H., et al. (2021) Replication and Cross-Validation of Type 2 Diabetes Subtypes Based on Clinical Variables: An IMI-RHAPSODY Study. Diabetologia, 64, 1982-1989. [Google Scholar] [CrossRef] [PubMed]
[30] Prasad, R.B., Asplund, O., et al. (2022) Subgroups of Patients with Young-Onset Type 2 Diabetes in India Reveal Insulin Deficiency as a Major Driver. Diabetologia, 65, 65-78. [Google Scholar] [CrossRef] [PubMed]
[31] Xiong, X.F., Yang, Y., Wei, L., et al. (2021) Identification of Two Novel Subgroups in Patients with Diabetes Mellitus and Their Association with Clinical Outcomes: A Two-Step Cluster Analysis. Journal of Diabetes Investigation, 12, 1346-1358. [Google Scholar] [CrossRef] [PubMed]
[32] Herder, C., Maalmi, H., Strassburger, K., et al. (2021) Differences in Biomarkers of Inflammation between Novel Subgroups of Recent-Onset Diabetes. Diabetes, 70, 1198-1208. [Google Scholar] [CrossRef] [PubMed]
[33] Udler, M.S., Kim, J., Von Grotthuss, M., et al. (2018) Type 2 Diabetes Genetic Loci Informed by Multi-Trait Associations Point to Disease Mechanisms and Subtypes: A Soft Clustering Analysis. PLOS Medicine, 15, e1002654. [Google Scholar] [CrossRef] [PubMed]
[34] Schwartz, S.S., Epstein, S., Corkey, B.E., et al. (2016) The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classifica-tion Schema. Diabetes Care, 39, 179-186. [Google Scholar] [CrossRef] [PubMed]

为你推荐